Key points are not available for this paper at this time.
// Fei Ma 1, * , Wenjie Zhu 1, * , Yanfang Guan 2 , Ling Yang 2 , Xuefeng Xia 3 , Shanshan Chen 1 , Qiao Li 1 , Xiuwen Guan 1 , Zongbi Yi 1 , Haili Qian 4 , Xin Yi 2 , Binghe Xu 1 1 Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China 2 Geneplus-Beijing, Beijing, China 3 Houston Methodist Research Institute, Weill Cornell School of Medicine, Houston, TX, USA 4 State Key Laboratory of Molecular Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China * These authors have contributed equally to this work Correspondence to: Binghe Xu, email: bhxu@hotmail.com Keywords: circulating tumor DNA, dynamics, progression, metastatic breast cancer, anti-HER2 therapy Received: May 11, 2016 Accepted: August 25, 2016 Published: September 1, 2016 ABSTRACT Background: Most studies utilizing circulating tumor DNA (ctDNA) to monitor disease interrogated only one or a few genes and failed to develop workable criteria to inform clinical practice. We evaluated the feasibility of detecting resistance to anti-HER2 therapy by serial gene-panel ctDNA sequencing. Results: Primary therapeutic resistance was identified in 6 out of 14 patients with events of progressive disease. For this subset comparison of pre- and post-treatment ctDNA assay results revealed that HER2 amplification concurred with disease progression (4/6, 66.7%). Mutations in TP53 (3/6, 50.0%) and genes implicated in the PI3K/mTOR pathway (3/6, 50.0%) were also dominant markers of resistance. Together, resistance to HER2 blockade should be indicated during treatment if any of the following situations applies: 1) recurrence or persistence of HER2 amplification in the blood; 2) emergence or ≥20% increase in the fraction of mutations in any of these resistance-related genes including TP53/PIK3CA/MTOR/PTEN . Compared with CT scans, dynamic ctDNA profiling utilizing pre-defined criteria was sensitive in identifying drug resistance (sensitivity 85.7%, specificity 55.0%), with a concordance rate up to 82.1%. Besides, the ctDNA criteria had a discriminating role in the prognosis of HER2-positive metastatic breast cancer. Methods: 52 plasma samples were prospectively collected from 18 patients with HER2-positive metastatic breast cancer who were treated with an oral anti-HER1/HER2 tyrosine kinase inhibitor ( ClinicalTrials.gov NCT01937689). ctDNA was assayed by gene-panel target-capture next-generation sequencing. Conclusions: Longitudinal gene-panel ctDNA sequencing could be exploited to determine resistance and guide the precise administration of anti-HER2 targeted therapy in the metastatic setting.
Ma et al. (Thu,) studied this question.